Patent intelligence · US
US 10835514
Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
Patent details — US 10835514
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2020
- Expiration
- Nov 12, 2040
- Applicant
- THERON PHARMACEUTICALS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/40, A61K31/403, A61K31/58
Quick answer
US 10835514 (Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives) is held by THERON PHARMACEUTICALS, INC.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- THERON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/40, A61K31/403, A61K31/58, A61K47/26, A61K9/0075
More from THERON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Frequently asked questions
What is US patent 10835514?
US 10835514 (Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives) is held by THERON PHARMACEUTICALS, INC.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10835514?
THERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 10835514 expire?
Our index shows an expiration date of Nov 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.